Observe Medical provides update on strong UnoMeter[TM] momentum in UK and Irish markets
Oslo, 3 June 2024 – Observe Medical ASA ("the Company" or "Observe Medical") continues to see positive momentum in the re-adoption of its UnoMeter™ brand of medical devices into NHS and across private hospitals in the United Kingdom and Ireland.
Building on previous announcements, Observe Medical confirms that since the start of 2024, UnoMeter™ products have been delivered to over 30 hospitals within 11 NHS Trusts in England. UnoMeter™ 500 (urinemeter) and UnoMeter™ Abdopressure™ (IAP) are experiencing strong demand, further solidified by their inclusion on both the English and Scottish Urology Frameworks.
Positive news continues in Ireland as well, with UnoMeter™ products delivered to the National Drugs Catalogue (NDC) and anticipated availability in hospitals within days. This widespread reacceptance reflects the ongoing enthusiasm from clinicians, nurses, and end-users who value the effectiveness of UnoMeter™ devices.
For further information, please contact:
Jørgen Mann, Interim CEO Observe Medical
Mobile: +45 408 67 558
E-mail: [email protected]
Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: [email protected]
About Observe Medical
Observe Medical is a Nordic medtech company that develops, markets and sells innovative medtech products for the global market. The Company is committed to improving patient welfare and patient outcomes, improving clinical data accuracy and promoting positive health economics.
The Company seeks to drive growth by leveraging its expertise in sales and commercialization of its broad portfolio of medical technology products, mainly in urine measurement and ultrasound, in combination with targeted M&A and distribution. Observe Medical is working with a network of leading distributors to provide outstanding solutions for healthcare professionals globally.
The Company is headquartered in Oslo, Norway.
Further information is available at www.observemedical.com.
